BBIO
Price:
$30.7
Market Cap:
$5.77B
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for ...[Read more]
Industry
Biotechnology
IPO Date
2019-06-27
Stock Exchange
NASDAQ
Ticker
BBIO
According to BridgeBio Pharma, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 6.95B. This represents a change of 5.12% compared to the average of 6.62B of the last 4 quarters.
The mean historical Enterprise Value of BridgeBio Pharma, Inc. over the last ten years is 4.41B. The current 6.95B Enterprise Value has changed 15.68% with respect to the historical average. Over the past ten years (40 quarters), BBIO's Enterprise Value was at its highest in in the June 2021 quarter at 9.96B. The Enterprise Value was at its lowest in in the June 2018 quarter at 0.
Average
4.41B
Median
3.42B
Minimum
2.16B
Maximum
8.53B
Discovering the peaks and valleys of BridgeBio Pharma, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 221.21%
Maximum Annual Enterprise Value = 8.53B
Minimum Annual Increase = -56.15%
Minimum Annual Enterprise Value = 2.16B
Year | Enterprise Value | Change |
---|---|---|
2023 | 7.94B | 221.21% |
2022 | 2.47B | -33.95% |
2021 | 3.74B | -56.15% |
2020 | 8.53B | 149.44% |
2019 | 3.42B | 58.17% |
2018 | 2.16B | -16.70% |
The current Enterprise Value of BridgeBio Pharma, Inc. (BBIO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
4.72B
5-year avg
5.22B
10-year avg
4.41B
BridgeBio Pharma, Inc.’s Enterprise Value is greater than IVERIC bio, Inc. (5.14B), greater than Blueprint Medicines Corporation (6.16B), greater than Amylyx Pharmaceuticals, Inc. (89.50M), less than Karuna Therapeutics, Inc. (12.43B), greater than Day One Biopharmaceuticals, Inc. (1.01B), greater than Mirati Therapeutics, Inc. (3.91B), greater than Terns Pharmaceuticals, Inc. (458.36M), greater than Apellis Pharmaceuticals, Inc. (5.11B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than PTC Therapeutics, Inc. (2.17B), greater than Krystal Biotech, Inc. (4.95B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Madrigal Pharmaceuticals, Inc. (4.91B), greater than Acumen Pharmaceuticals, Inc. (93.64M), greater than Inozyme Pharma, Inc. (343.89M), greater than X4 Pharmaceuticals, Inc. (40.79M),
Company | Enterprise Value | Market cap |
---|---|---|
5.14B | $5.51B | |
6.16B | $5.47B | |
89.50M | $161.36M | |
12.43B | $12.60B | |
1.01B | $1.25B | |
3.91B | $4.12B | |
458.36M | $549.60M | |
5.11B | $5.00B | |
8.24B | $8.19B | |
2.17B | $2.43B | |
4.95B | $5.29B | |
915.81M | $794.69M | |
4.91B | $5.30B | |
93.64M | $133.38M | |
343.89M | $312.42M | |
40.79M | $109.78M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BridgeBio Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BridgeBio Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is BridgeBio Pharma, Inc.'s Enterprise Value?
What is the highest Enterprise Value for BridgeBio Pharma, Inc. (BBIO)?
What is the 3-year average Enterprise Value for BridgeBio Pharma, Inc. (BBIO)?
What is the 5-year average Enterprise Value for BridgeBio Pharma, Inc. (BBIO)?
How does the current Enterprise Value for BridgeBio Pharma, Inc. (BBIO) compare to its historical average?